A case labeled the Oslo patient is reshaping what long-term HIV control can look like. After a stem cell transplant from his brother, who carries a protective CCR5 mutation that blocks viral entry, the man now shows no detectable virus and no rebound despite stopping antiretroviral therapy under medical supervision.
Doctors used an allogeneic bone marrow transplant originally intended to treat a blood disorder, not HIV itself. The donor’s cells lack functional CCR5 receptors, one of the main coreceptors HIV uses to infect CD4 T cells. As the patient’s immune system was replaced, viral reservoirs that normally persist in lymphoid tissue and bone marrow were pushed toward what clinicians cautiously call a state of functional cure rather than complete eradication.
The Oslo patient joins a tiny group of individuals worldwide who reached durable remission through similar procedures, which carry significant risks and are not viable for routine HIV care. For researchers, however, each such case offers a rare in vivo experiment in reservoir depletion, immune reconstitution and the marginal effects that specific genetic barriers can exert on viral persistence.
